Oral vitamin B3 derivative cuts risk of new skin cancers

Taking a form of vitamin B3 promises to be a simple prevention for the recurrence of non-melanoma skin cancers in high-risk patients, according to new Australian research out of the University of Sydney. The ONTRAC (Oral Nicotinamide To Reduce Actinic Cancer) study results, published today in the New England Journal of Medicine, show that a year of treatment with the B3 derivative nicotinamide is linked to a significantly (23 per cent) lower risk of common, non-melanoma skin cancer compared to placebo.

To continue reading this article, please Log In or Sign Up for access.